Jushi Holdings Earnings Call Balances Growth And Debt

Jushi Holdings Inc ((TSE:JUSH)) has held its Q1 earnings call. Read on for the main highlights of the call.

Jushi Holdings Inc.’s latest earnings call struck a cautiously upbeat tone as management highlighted steady revenue growth, expanding margins, stronger operating cash flow and a more liquid balance sheet. Executives balanced this optimism with frank discussion of persistent pricing pressure, a wider net loss, and a still-heavy debt load amid regulatory and implementation uncertainty.

Modest revenue growth in a challenging market

Jushi reported Q1 2026 revenue of $66.4 million, a 4% year‑over‑year increase from $63.8 million, underscoring modest top‑line momentum in a pressured pricing environment. Retail revenue inched up to $57.9 million from $56.8 million, while wholesale revenue rose more sharply to $8.6 million from $7.0 million, a 22.2% gain.

Margin expansion supports improving profitability

Gross profit climbed to $29.9 million, lifting gross margin to 45.0% from 40.4% a year earlier as operational efficiencies and product mix improvements took hold. Adjusted EBITDA rose to $11.4 million, a 17.2% margin versus 15.4% last year, signaling better underlying profitability despite flat retail volumes.

Operational and product momentum across the portfolio

Management emphasized upgrades in product quality and production volumes across its grower‑processor footprint, which have begun to translate into stronger branded performance. The company rolled out 567 new SKUs, a 45% year‑over‑year increase, delivering record quarterly third‑party packaged goods sales as Flower Foundry and Hijinks logged mid‑ to high‑single‑digit revenue and unit growth.

Wholesale distribution broadens market reach

Jushi expanded its wholesale footprint by adding 32 new dispensary customers in the quarter, including 20 in Massachusetts and 8 in Ohio. This broader distribution base is helping drive the wholesale segment’s outperformance and positions the company to capture share in key growth markets as regulatory frameworks evolve.

Stronger operating cash flow and liquidity buffer

Cash flow from operations improved to $8.6 million from $7.5 million a year earlier, underscoring the impact of margin gains and tighter working‑capital management. Jushi ended the quarter with approximately $42.3 million in cash, supplemented by incremental liquidity from its recently completed refinancing, giving it more flexibility to navigate market volatility.

Strategic refinancing reshapes the balance sheet

The company executed a $160 million first‑lien senior secured term loan featuring a 4% original issue discount and a 12.5% coupon, with interest‑only payments for 36 months. Proceeds were used to repay prior debt, boost liquidity and avoid equity dilution, and management underscored alignment by noting the CEO’s increased personal capital participation in the financing.

Federal rescheduling seen as a major tailwind

Management framed the final order rescheduling state‑licensed medical cannabis to Schedule III, effective April 28, as a transformative regulatory milestone for the industry. They expect the move to eventually remove the Section 280E tax deduction disallowance for state licensees, a material long‑term benefit given medical sales are projected to represent roughly 60% of 2025 revenue.

Market‑specific wins and expansion upside

Retail performance was particularly strong in Ohio and Virginia, supported by four new Ohio dispensaries opened since Q1 2025 and robust 4/20 results with higher net sales, units and orders year over year. In Massachusetts, a regulatory change lifting the retail license cap from three to six for a single operator presents a strategic opportunity for Jushi to scale and participate in potential market consolidation.

Retail growth constrained by pricing pressure

Despite geographic pockets of strength, overall retail revenue grew only modestly, up $1.1 million year over year as competitive pricing and promotional activity weighed on average selling prices. Management acknowledged that discounting has become more prevalent across several markets, forcing a continued focus on cost control, product differentiation and loyalty programs.

Net loss widens on higher interest and refinancing costs

Jushi posted a net loss of $19.8 million for the quarter, compared with a $17.0 million loss a year earlier, as interest and refinancing costs outpaced operating improvements. Interest expense reached $10.4 million, and the refinancing triggered a $5.0 million loss on debt, partially offset by a $2.3 million fair value gain on derivatives.

Elevated debt load remains a key overhang

Total debt subject to repayment stood at $222.1 million as of March 31, excluding $21.5 million in disputed promissory notes, leaving the company meaningfully levered despite its enhanced liquidity. Management argued that the new capital structure buys time and optionality, but investors will likely watch leverage metrics closely as the industry’s regulatory outlook evolves.

Refinancing terms trade higher interest for flexibility

The new term loan’s 12.5% coupon and 4% original issue discount provide near‑term breathing room through 36 months of interest‑only payments but add to the company’s interest burden. While the facility includes just a single minimum‑liquidity covenant, the sizable future principal obligations create refinancing and repayment risk that will require sustained cash flow growth to manage.

Regulatory timing and implementation still uncertain

Executives cautioned that while federal rescheduling is a major positive, the ultimate financial impact depends on pending guidance and the mechanics of implementation, including potential retroactivity. State‑level decisions, such as the outcome of Virginia’s adult‑use discussions, will significantly influence the timing and magnitude of revenue, margin and investment opportunities.

Competitive dynamics driving portfolio reshaping

Competition remains intense in core markets like Illinois, Massachusetts and Pennsylvania, and lower wholesale demand in Virginia partially offset gains elsewhere. Jushi is responding by evaluating four to five store relocations and moving to dispose of underperforming assets, including a planned sale of its Peoria, Illinois location, pending regulatory approval.

Disciplined near‑term expenses and CapEx plans

Operating expenses ticked up to $28.3 million from $27.6 million as higher employee costs, professional and legal fees, and share‑based compensation flowed through the income statement. Capital spending for fiscal 2026 is expected to remain modest at $9 million to $13 million, with larger build‑outs deferred until regulatory paths are clearer, likely beyond 2027.

Guidance underscores capital discipline and rescheduling upside

Management’s outlook centers on careful capital deployment, maintaining liquidity and capturing benefits from federal rescheduling over time, with maintenance CapEx targeted at roughly $4 million to $5 million and growth CapEx at $5 million to $8 million for 2026. They reiterated that the company’s $42.3 million cash balance, $160 million term loan and improving margins should support operations while rescheduling, particularly for medical sales, gradually reduces tax burdens subject to how regulators implement the new framework.

Jushi’s earnings call painted a picture of a company strengthening its operations and positioning for regulatory tailwinds while still managing the weight of leverage and pricing pressure. For investors, the story hinges on whether margin gains, expanding wholesale distribution and eventual tax relief can outpace interest costs and competitive headwinds, turning today’s cautious optimism into durable shareholder value.